TargetCoagulation factor XI(Homo sapiens (Human))
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Affinity DataIC50: 0.400nMAssay Description:Inhibition of human F11a using D-Leu-Pro-Arg*Rh110-D-Pro as substrate preincubated for 60 mins followed by substrate addition and measured after 60 m...More data for this Ligand-Target Pair
TargetCoagulation factor XI(Homo sapiens (Human))
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Affinity DataIC50: 0.700nMAssay Description:Inhibition of human F11a using D-Leu-Pro-Arg*Rh110-D-Pro as substrate preincubated for 60 mins followed by substrate addition and measured after 60 m...More data for this Ligand-Target Pair
TargetCoagulation factor XI(Homo sapiens (Human))
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Affinity DataIC50: 0.700nMAssay Description:Inhibition of human F11a using D-Leu-Pro-Arg*Rh110-D-Pro as substrate preincubated for 60 mins followed by substrate addition and measured after 60 m...More data for this Ligand-Target Pair
TargetPlasma kallikrein(Homo sapiens (Human))
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Affinity DataIC50: 1nMAssay Description:Inhibition of PKL (unknown origin) using D-Leu-Pro-Arg*Rh110-D-Pro as substrate preincubated for 60 mins followed by substrate addition and measured ...More data for this Ligand-Target Pair
Affinity DataIC50: 1nMpH: 7.3 T: 2°CAssay Description:Each well of the MBP-coated ScintiPlates held 100 ul of a solution containing 20 mM HEPES pH 7.3, 5 mM MnCl2 (WNK1 and WNK4) or 3 mM MnCl2 (WNK2 and ...More data for this Ligand-Target Pair
TargetPlasma kallikrein(Homo sapiens (Human))
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Affinity DataIC50: 1nMAssay Description:Inhibition of PKL (unknown origin) using D-Leu-Pro-Arg*Rh110-D-Pro as substrate preincubated for 60 mins followed by substrate addition and measured ...More data for this Ligand-Target Pair
TargetPlasma kallikrein(Homo sapiens (Human))
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Affinity DataIC50: 2nMAssay Description:Inhibition of PKL (unknown origin) using D-Leu-Pro-Arg*Rh110-D-Pro as substrate preincubated for 60 mins followed by substrate addition and measured ...More data for this Ligand-Target Pair
TargetPlasma kallikrein(Homo sapiens (Human))
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Affinity DataIC50: 2nMAssay Description:Inhibition of PKL (unknown origin) using D-Leu-Pro-Arg*Rh110-D-Pro as substrate preincubated for 60 mins followed by substrate addition and measured ...More data for this Ligand-Target Pair
TargetCoagulation factor XI(Homo sapiens (Human))
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Affinity DataIC50: 2nMAssay Description:Inhibition of human F11a using D-Leu-Pro-Arg*Rh110-D-Pro as substrate preincubated for 60 mins followed by substrate addition and measured after 60 m...More data for this Ligand-Target Pair
TargetCoagulation factor XI(Homo sapiens (Human))
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Affinity DataIC50: 3nMAssay Description:Inhibition of human F11a using D-Leu-Pro-Arg*Rh110-D-Pro as substrate preincubated for 60 mins followed by substrate addition and measured after 60 m...More data for this Ligand-Target Pair
TargetCoagulation factor XI(Homo sapiens (Human))
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Affinity DataIC50: 3nMAssay Description:Inhibition of human F11a using D-Leu-Pro-Arg*Rh110-D-Pro as substrate preincubated for 60 mins followed by substrate addition and measured after 60 m...More data for this Ligand-Target Pair
TargetPlasma kallikrein(Homo sapiens (Human))
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Affinity DataIC50: 3nMAssay Description:Inhibition of PKL (unknown origin) using D-Leu-Pro-Arg*Rh110-D-Pro as substrate preincubated for 60 mins followed by substrate addition and measured ...More data for this Ligand-Target Pair
TargetCoagulation factor XI(Homo sapiens (Human))
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Affinity DataIC50: 3nMAssay Description:Inhibition of human F11a using D-Leu-Pro-Arg*Rh110-D-Pro as substrate preincubated for 60 mins followed by substrate addition and measured after 60 m...More data for this Ligand-Target Pair
TargetPlasma kallikrein(Homo sapiens (Human))
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Affinity DataIC50: 4nMAssay Description:Inhibition of PKL (unknown origin) using D-Leu-Pro-Arg*Rh110-D-Pro as substrate preincubated for 60 mins followed by substrate addition and measured ...More data for this Ligand-Target Pair
TargetCoagulation factor XI(Homo sapiens (Human))
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Affinity DataIC50: 4nMAssay Description:Inhibition of human F11a using D-Leu-Pro-Arg*Rh110-D-Pro as substrate preincubated for 60 mins followed by substrate addition and measured after 60 m...More data for this Ligand-Target Pair
TargetCoagulation factor XI(Homo sapiens (Human))
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Affinity DataIC50: 4nMAssay Description:Inhibition of human F11a using D-Leu-Pro-Arg*Rh110-D-Pro as substrate preincubated for 60 mins followed by substrate addition and measured after 60 m...More data for this Ligand-Target Pair
Affinity DataIC50: 5nMpH: 7.3 T: 2°CAssay Description:Each well of the MBP-coated ScintiPlates held 100 ul of a solution containing 20 mM HEPES pH 7.3, 5 mM MnCl2 (WNK1 and WNK4) or 3 mM MnCl2 (WNK2 and ...More data for this Ligand-Target Pair
Affinity DataIC50: 6nMpH: 7.3 T: 2°CAssay Description:Each well of the MBP-coated ScintiPlates held 100 ul of a solution containing 20 mM HEPES pH 7.3, 5 mM MnCl2 (WNK1 and WNK4) or 3 mM MnCl2 (WNK2 and ...More data for this Ligand-Target Pair
TargetCoagulation factor XI(Homo sapiens (Human))
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Affinity DataIC50: 6nMAssay Description:Inhibition of human F11a using D-Leu-Pro-Arg*Rh110-D-Pro as substrate preincubated for 60 mins followed by substrate addition and measured after 60 m...More data for this Ligand-Target Pair
TargetCoagulation factor XI(Homo sapiens (Human))
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Affinity DataIC50: 6nMAssay Description:Inhibition of human F11a using D-Leu-Pro-Arg*Rh110-D-Pro as substrate preincubated for 60 mins followed by substrate addition and measured after 60 m...More data for this Ligand-Target Pair
TargetPlasma kallikrein(Homo sapiens (Human))
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Affinity DataIC50: 6nMAssay Description:Inhibition of PKL (unknown origin) using D-Leu-Pro-Arg*Rh110-D-Pro as substrate preincubated for 60 mins followed by substrate addition and measured ...More data for this Ligand-Target Pair
TargetPlasma kallikrein(Homo sapiens (Human))
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Affinity DataIC50: 7nMAssay Description:Inhibition of PKL (unknown origin) using D-Leu-Pro-Arg*Rh110-D-Pro as substrate preincubated for 60 mins followed by substrate addition and measured ...More data for this Ligand-Target Pair
TargetComplement factor D(Homo sapiens (Human))
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Affinity DataIC50: 8nMAssay Description:Inhibition of human complement FD by TR-FRET assayMore data for this Ligand-Target Pair
Affinity DataIC50: 9nMpH: 7.3 T: 2°CAssay Description:Each well of the MBP-coated ScintiPlates held 100 ul of a solution containing 20 mM HEPES pH 7.3, 5 mM MnCl2 (WNK1 and WNK4) or 3 mM MnCl2 (WNK2 and ...More data for this Ligand-Target Pair
TargetCoagulation factor XI(Homo sapiens (Human))
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Affinity DataIC50: 9nMAssay Description:Inhibition of human F11a using D-Leu-Pro-Arg*Rh110-D-Pro as substrate preincubated for 60 mins followed by substrate addition and measured after 60 m...More data for this Ligand-Target Pair
TargetPlasma kallikrein(Homo sapiens (Human))
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Affinity DataIC50: 9nMAssay Description:Inhibition of PKL (unknown origin) using D-Leu-Pro-Arg*Rh110-D-Pro as substrate preincubated for 60 mins followed by substrate addition and measured ...More data for this Ligand-Target Pair
TargetCoagulation factor XI(Homo sapiens (Human))
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Affinity DataIC50: 10nMAssay Description:Inhibition of N-terminal human plasma F11a catalytic domain expressed in Escherichia coli strain BL21(DE3) using D-Leu-Pro-Arg*Rh110-D-Pro as substra...More data for this Ligand-Target Pair
TargetCoagulation factor XI(Homo sapiens (Human))
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Affinity DataIC50: 10nMAssay Description:Inhibition of N-terminal human plasma F11a catalytic domain expressed in Escherichia coli strain BL21(DE3) using D-Leu-Pro-Arg*Rh110-D-Pro as substra...More data for this Ligand-Target Pair
TargetPlasma kallikrein(Homo sapiens (Human))
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Affinity DataIC50: 11nMAssay Description:Inhibition of PKL (unknown origin) using D-Leu-Pro-Arg*Rh110-D-Pro as substrate preincubated for 60 mins followed by substrate addition and measured ...More data for this Ligand-Target Pair
TargetCoagulation factor XI(Homo sapiens (Human))
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Affinity DataIC50: 12nMAssay Description:Inhibition of human F11a using D-Leu-Pro-Arg*Rh110-D-Pro as substrate preincubated for 60 mins followed by substrate addition and measured after 60 m...More data for this Ligand-Target Pair
Affinity DataIC50: 14nMAssay Description:Inhibition of chymotrypsin like activity of mouse spleen 20S proteasome beta5i subunit using Suc-Leu-Leu-Val-Tyr-AMC as substrate preincubated for 15...More data for this Ligand-Target Pair
TargetCoagulation factor XI(Homo sapiens (Human))
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Affinity DataIC50: 15nMAssay Description:Inhibition of human F11a using D-Leu-Pro-Arg*Rh110-D-Pro as substrate preincubated for 60 mins followed by substrate addition and measured after 60 m...More data for this Ligand-Target Pair
TargetPlasma kallikrein(Homo sapiens (Human))
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Affinity DataIC50: 16nMAssay Description:Inhibition of PKL (unknown origin) using D-Leu-Pro-Arg*Rh110-D-Pro as substrate preincubated for 60 mins followed by substrate addition and measured ...More data for this Ligand-Target Pair
TargetUrokinase-type plasminogen activator(Homo sapiens (Human))
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Affinity DataIC50: 16nMAssay Description:Inhibition of human urokinase using fluorescent peptide as substrate by florescence assayMore data for this Ligand-Target Pair
Affinity DataIC50: 17nMAssay Description:Inhibition of chymotrypsin like activity of mouse spleen 20S proteasome beta5i subunit using Suc-Leu-Leu-Val-Tyr-AMC as substrate preincubated for 15...More data for this Ligand-Target Pair
TargetCoagulation factor XI(Homo sapiens (Human))
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Affinity DataIC50: 17nMAssay Description:Inhibition of human F11a using D-Leu-Pro-Arg*Rh110-D-Pro as substrate preincubated for 60 mins followed by substrate addition and measured after 60 m...More data for this Ligand-Target Pair
TargetUrokinase-type plasminogen activator(Homo sapiens (Human))
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Affinity DataIC50: 20nMAssay Description:Inhibition of human uPA using fluorescent peptide as substrate by florescence assayMore data for this Ligand-Target Pair
TargetUrokinase-type plasminogen activator(Homo sapiens (Human))
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Affinity DataIC50: 20nMAssay Description:Inhibition of human uPA using fluorescent peptide as substrate by florescence assayMore data for this Ligand-Target Pair
TargetPlasma kallikrein(Homo sapiens (Human))
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Affinity DataIC50: 21nMAssay Description:Inhibition of PKL (unknown origin) using D-Leu-Pro-Arg*Rh110-D-Pro as substrate preincubated for 60 mins followed by substrate addition and measured ...More data for this Ligand-Target Pair
TargetPlasma kallikrein(Homo sapiens (Human))
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Affinity DataIC50: 25nMAssay Description:Inhibition of PKL (unknown origin) using D-Leu-Pro-Arg*Rh110-D-Pro as substrate preincubated for 60 mins followed by substrate addition and measured ...More data for this Ligand-Target Pair
TargetCoagulation factor IX(Homo sapiens (Human))
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Affinity DataIC50: 30nMAssay Description:Inhibition of human F9a using fluorescent peptide as substrate by florescence assayMore data for this Ligand-Target Pair
Affinity DataIC50: 30nMAssay Description:Inhibition of human thrombin using fluorescent peptide as substrate by florescence assayMore data for this Ligand-Target Pair
TargetCoagulation factor IX(Homo sapiens (Human))
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Affinity DataIC50: 40nMAssay Description:Inhibition of human F9a using fluorescent peptide as substrate by florescence assayMore data for this Ligand-Target Pair
TargetComplement factor D(Homo sapiens (Human))
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Affinity DataIC50: 40nMAssay Description:Inhibition of human complement FD by TR-FRET assayMore data for this Ligand-Target Pair
TargetComplement factor D(Homo sapiens (Human))
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Affinity DataIC50: 40nMAssay Description:Inhibition of human complement FD by TR-FRET assayMore data for this Ligand-Target Pair
TargetCoagulation factor XI(Homo sapiens (Human))
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Affinity DataIC50: 40nMAssay Description:Inhibition of human F11a using D-Leu-Pro-Arg*Rh110-D-Pro as substrate preincubated for 60 mins followed by substrate addition and measured after 60 m...More data for this Ligand-Target Pair
TargetPlasma kallikrein(Homo sapiens (Human))
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Affinity DataIC50: 41nMAssay Description:Inhibition of PKL (unknown origin) using D-Leu-Pro-Arg*Rh110-D-Pro as substrate preincubated for 60 mins followed by substrate addition and measured ...More data for this Ligand-Target Pair
Affinity DataIC50: 41nMpH: 7.3 T: 2°CAssay Description:Each well of the MBP-coated ScintiPlates held 100 ul of a solution containing 20 mM HEPES pH 7.3, 5 mM MnCl2 (WNK1 and WNK4) or 3 mM MnCl2 (WNK2 and ...More data for this Ligand-Target Pair
TargetCoagulation factor XI(Homo sapiens (Human))
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Affinity DataIC50: 45nMAssay Description:Inhibition of N-terminal human plasma F11a catalytic domain expressed in Escherichia coli strain BL21(DE3) using D-Leu-Pro-Arg*Rh110-D-Pro as substra...More data for this Ligand-Target Pair
TargetUrokinase-type plasminogen activator(Homo sapiens (Human))
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Novartis Institutes for BioMedical Research
Curated by ChEMBL
Affinity DataIC50: 47nMAssay Description:Inhibition of human urokinase using fluorescent peptide as substrate by florescence assayMore data for this Ligand-Target Pair
![](/img/powered_by_small.gif)